Tobacco has known associations with psychosis, but less is known about the relationship between tobacco use and subclinical psychotic-like experiences (PLEs). This study sought to disentangle the association of tobacco with PLEs in a large nationally representative sample—read the article to learn what the authors found.
Each year in the US, millions of people misuse prescription opioids. To combat this, it's important to understand the motivations. This analysis of data from the National Survey on Drug Use and Health examined characteristics of people with opioid use but not misuse, those with misuse but not use disorders, and the motivations of each group.
Although smoking prevalence in the US has declined overall, is it declining among those with mental illness and substance use problems? These authors drew from the National Survey on Drug Use and Health to track trends from 2005 to 2014 in daily and nondaily smoking. Read the article to see what they found.
Gabapentin has started to evolve as a drug of abuse over the past few years. As a noncontrolled substance, patients may obtain it rather easily for a host of off-label uses, most with limited to no evidence. High-dose gabapentin use can be predictive of opiate misuse disorder. This study investigated the relationship between gabapentin use and dose with substance use disorders prior to inpatient mental health treatment. Read on to find out more.
Cannabis use is increasingly visible as policy shifts toward legalization in many states. What should clinicians know about treating patients who use cannabis? This ASCP Corner article examines the prevalence of cannabis use and cannabis use disorders among individuals with psychiatric disorders, user characteristics, impact on psychiatric symptoms, and adverse effects on treatment.
Caffeine is the world's most-consumed psychoactive substance. It is also considered a performance-enhancing substance by athletes and bodybuilders. Here, read about caffeine's psychogenic effect on a bodybuilder who also used nonprescribed testosterone and amphetamine/dextroamphetamine.
How common is illicit drug use among current and former cigarette smokers? If marijuana isn' t considered illicit, does that change the prevalence of illicit drug use? Can illicit drug use interfere with smoking abstinence? Learn about these topics in this CME journal article.
For preventing prescription drug misuse in young adults, it's important to know the source from which they obtained the drugs. This study used data from a large nationally representative sample to examine prescription drug misuse, drug sources, and substance use disorder in relation to educational status in US young adults.
Cigarette smokers are more likely than nonsmokers to use cannabis, and cannabis users are cigarette smokers more often than are nonusers. Read this article to learn how cannabis use relates to transitions in cigarette smoking over time.
Adults with ADHD have high rates of cannabis use, so they probably have high rates of cannabis withdrawal when they stop using cannabis, right? This study aimed to describe cannabis withdrawal, motivations to quit, and strategies to quit cannabis. Read on to find out more.
Tune in to this podcast as experts discuss 2 patient cases—one involving co-occurring insomnia and depression and another comprising PTSD, substance abuse, insomnia, and nightmares. Drs Benca and Buysse explain how to effectively diagnose and manage these complex cases based on the latest diagnostic criteria and evidence from clinical trials.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”